G20 Health Minister’s Meeting concludes in Gandhinagar, Gujarat

Global Initiative on Digital Health launched at the G2O Health Minister’s Meeting

Lupin acquires Boehringer Ingelheim's brands Ondero and Ondero Met to expand diabetes portfolio in India

This acquisition strengthens Lupin's commitment to providing superior treatment options for patients navigating the complexities of diabetes

SSI Strategy to acquires NDA Group partner to form global life sciences consultancy

Combination creates an integrated provider of drug development and regulatory consulting services serving a complementary client base

Mobile addicted generation heading towards hearing disorders: Survey

The survey findings for Delhi-NCR revealed that speech sound disorders exhibit higher prevalence rates in the 6-12 years age group

Boehringer Ingelheim receives FDA approval for Senvelgo to treat diabetes in cat

Senvelgo is the first liquid once-daily, orally administered prescription medication to improve glycemic control in cats with diabetes mellitus

Parexel and Partex collaborate to leverage on AI and Big Data to accelerate drug delivery

Collaboration combines clinical research expertise with artificial intelligence capabilities to help drug developers better understand the probability of clinical success for their assets

Hikal posts Q1 FY 24 consolidated PAT at Rs. 6.92 Cr

US FDA approval is in line with de-risking strategy for additional API site to service our global customer base

USFDA approves Merck’s ERVEBO for use in children 12 months of age and older

Merck continues progress in helping to protect people at risk of Zaire ebolavirus disease

Jemperli plus chemotherapy approved in the US as the first new frontline treatment option for dMMR/MSI-H primary advanced or recurrent endometrial cancer

Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy

USFDA accepts biologics license application for GC Biopharma's GC5107B